ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.